Evidence map›Paper›PMID 40790322›Full record

ArticleScientific reports2025

Global, regional, and national burden of nonrheumatic calcific aortic valve disease based on GBD study 2021.

Baiqiang Wang, Zeyuan Mei, Hong Yang, Wei Gao, Lianyue Ma, Guipeng An

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Baiqiang Wang *State Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China.
Zeyuan Mei *State Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China.
Hong YangJinan Vocational College of Nursing, Jinan, China.
Wei GaoState Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China.
Lianyue MaState Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China. malianyue5407@126.com.
Guipeng AnState Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China. guipengan@hotmail.com.

Funding

National Natural Science Foundation of China 81800382
6 · The paper itself

Abstract

Calcific aortic valve disease (CAVD) is among the most prevalent forms of nonrheumatic valvular heart disease, imposing a substantial global health burden. This study examined CAVD trends to provide insights for the development of effective prevention strategies. Using Global Burden of Disease Study 2021 (GBD 2021) data, we analyzed the age-standardized prevalence, incidence, mortality, and disability-adjusted life years (DALYs) of CAVD, along with trends, age- and sex-specific patterns, contributing factors, and projections through 2036. From 1992 to 2021, the number of global CAVD cases rose from 4.97 to 13.32 million and the age-standardized prevalence rate (ASPR) increased from 130.82 to 158.35 per 100,000 people. While both the ASPR and age-standardized incidence rate (ASIR) steadily increased, the age-standardized mortality rate (ASMR) and age-standardized DALYs rate (ASDR) declined. The burden of CAVD progressively worsened with age. Males generally had higher prevalence and incidence rates compared with females. However, in individuals > 85 years, females exhibited significantly higher mortality and DALY burdens. The CAVD burden was positively correlated with the sociodemographic index (SDI); the correlation was stronger in High SDI regions compared with Low SDI regions, and this gap widened over the last three decades. Population growth and aging were the primary contributors to the increasing burden, while epidemiological transitions helped reduce the ASMR and ASDR in regions with a high SDI. By 2036, the ASPR, ASIR, ASMR, and ASDR of CAVD are projected to decline in the High and High-middle SDI regions. In contrast, the ASPR and ASIR are expected to continue to increase, whereas the ASMR and ASDR are anticipated to remain relatively stable in other SDI regions. Although significant progress has been made globally in the prevention and treatment of CAVD, the complex demographic and regional disparities underscore the need for targeted prevention and treatment strategies to further alleviate the burden and enhance patient outcomes.

Indexed as

Aortic ValveAortic Valve StenosisCalcinosisGlobal Burden of DiseaseAdolescentAdultAgedAged, 80 and overChildDisability-Adjusted Life YearsFemaleGlobal HealthHumansIncidenceInfantMaleCalcific aortic valve diseaseDisability-adjusted life yearsGlobal burden of diseaseIncidenceMortalityPrevalence

Identifiers

PMID40790322
PMCPMC12340002

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.